<DOC>
	<DOCNO>NCT00022126</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Giving drug different combination may kill cancer cell . Bone marrow transplantation allow doctor give high dos chemotherapy kill cancer cell . PURPOSE : Phase II trial compare effectiveness combination chemotherapy without donor bone marrow transplantation treat infant previously untreated acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Donor Bone Marrow Transplantation Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility dexamethasone-based induction chemotherapy follow augment Berlin-Frankfurt-Munster ( BFM ) consolidation chemotherapy without allogeneic bone marrow transplantation infant previously untreated acute lymphoblastic leukemia . - Determine event-free survival patient treat regimen . - Determine clinical prognostic feature associate outcome patient . - Compare biologic characteristic leukemia cell outcome patient . OUTLINE : This multicenter study . Patients receive induction therapy comprise oral dexamethasone 3 time daily day 1-14 ; daunorubicin IV day 1 , 8 , 15 ; vincristine IV day 1 , 8 , 15 , 22 ; asparaginase intramuscularly ( IM ) day 4 , 6 , 8 , 11 , 13 , 15 , 18 , 20 , 22 . Patients also receive methotrexate intrathecally ( IT ) day 1 , 8 , 15 ( day 4 22 overt CNS disease ) . Patients M1 M2 marrow induction therapy receive augment consolidation therapy blood count recover . Patients receive cyclophosphamide IV day 1 29 ; cytarabine IV subcutaneously ( SC ) day 2-5 , 9-12 , 30-33 , 37-40 ; oral mercaptopurine day 1-14 29-42 ; vincristine IV day 15 , 22 , 43 , 50 ; pegaspargase IM day 15 43 ; methotrexate IT day 1 , 8 , 15 . Patients receive bone marrow transplantation ( BMT ) proceed interim maintenance # 1 blood count recover . Patients receive methotrexate IT day 1 , 11 , 22 , 32 ; methotrexate IV vincristine IV day 1 , 11 , 22 , 32 , 43 ; pegaspargase IM day 2 23 . When blood count recover , patient receive delay intensification # 1 comprise vincristine IV day 1 , 8 , 15 , 43 , 50 ; doxorubicin IV day 1 , 8 , 15 ; oral dexamethasone 3 time daily day 1-7 15-21 ; pegaspargase IM day 4 43 ; cyclophosphamide IV day 29 ; methotrexate IT day 29 36 ; oral thioguanine day 29-42 ; cytarabine IV SC day 30-33 37-40 . When blood count recover , patient receive interim maintenance # 2 comprise vincristine interim maintenance # 1 ; methotrexate IT day 1 IV day 1 , 11 , 22 , 32 , 41 ; pegaspargase IM day 2 23 . When blood count recover , patient receive delay intensification # 2 comprise vincristine , doxorubicin , dexamethasone , pegaspargase , cyclophosphamide , cytarabine , thioguanine intensification # 1 . Patients also receive methotrexate IT day 1 29 . When blood count recover , patient receive maintenance therapy comprise methotrexate IT day 1 orally day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; vincristine IV day 1 , 29 , 57 ; oral dexamethasone 3 time daily day 1-5 , 29-33 , 57-61 ; oral mercaptopurine daily . Treatment repeat every 84 day 6 course . Patients allergy pegaspargase replace asparaginase IM day receive methotrexate IV interim maintenance # 1 # 2 daily 6 day place dose pegaspargase delay intensification # 1 # 2 . After augmented consolidation therapy , patient meet follow criterion may receive BMT place chemotherapy : - In remission - Exhibiting chromosome translocation involve 11q23 Ph+ { ( 9 ; 22 ) } - Available HLA-A , B , DR genotypic identical relative donor - No uncontrolled infection - Adequate organ function Within 3-4 week consolidation therapy , patient undergo allogeneic BMT receive cytarabine IV 1 hour day -8 -5 ; cyclophosphamide IV 30 minute day -7 -6 ; methylprednisolone IV twice daily day -2 0 . Patients also undergo total body irradiation twice daily day -3 0 . Patients receive allogeneic BMT day 0 . Patients also receive cyclosporine IV every 12 hour begin day -1 , switch oral possible , continue day 60 . Patients taper cyclosporine next 60-120 day . Patients follow every 2 month 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month 1-2 year , annually thereafter . PROJECTED ACCRUAL : A maximum 20-40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis previously untreated acute lymphoblastic leukemia ( ALL ) acute undifferentiated leukemia CNS testicular disease allow No L3 sIg+ ALL acute myelogenous leukemia At least 36 week gestation congenital ALL PATIENT CHARACTERISTICS : Age : Under 366 day diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Steroid therapy within 48 hour study allow complete blood count lumbar puncture result know No chronic steroid treatment disease Radiotherapy : Not specify Surgery : Not specify Other : No concurrent cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
</DOC>